66.93% of retail investor accounts lose money when trading CFDs / Spread betting with this provider.
Important Notice - Scam website
Important Notice - Fraud awareness
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 66.93% of retail investor accounts lose money when trading CFDs / Spread betting with this provider. You should consider whether you understand how CFDs / Spread betting work and whether you can afford to take the high risk of losing your money.
Important Notice - Scam website
Important Notice - Fraud awareness
The vast majority of retail investor accounts lose money when trading CFDs / Spread betting with this provider.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The vast majority of retail investor accounts lose money when trading CFDs / Spread betting with this provider. You should consider whether you understand how CFDs / Spread betting work and whether you can afford to take the high risk of losing your money.
ATFX
Language
    rch
    Client Portal
    Client Portal
    Open account
    Start trading
    rch

    Hutchison China Meditech share price: a pharma specialist

    One of the rules of pharma is that the more specialist a player is, the greater the margins and the longer the company in question is likely to hold onto its patent. In this way one can say that the Hutchison China Meditech share price is a play on a strategy which, once complete, should reward those backing the HCM share price.

    The reason for saying this is we have already seen the Hutchison China Meditech share price bottom out this year in March just below $15. This comes two years after the launch in China of Chi-Med’s colorectal cancer treatment Elunate, which was delivered in partnership with pharma giant Eli Lily.

    If anything, partnering with such an established name as Eli Lily added extra credibility to HCM shares with regard to this milestone initiative.

    Learn more about shares trading with us

     

    Investors appreciate the HCM share price Nasdaq listing

    It is well known that the Nasdaq market in the US trumps all others in terms of its appreciation and valuation of all things in the tech and pharma space. Therefore as far as HCM shares Nasdaq listing we are looking at the driving force in terms of liquidity.

    Recent newsflow has only helped investors in HCM shares, given that in the pandemic environment, pharma stocks of all shapes and sizes are particularly in focus.

    This is whether they are COVID-19 related or not. Indeed, it has been generally reported that due to hospitals diverting resources to the pandemic, early detection of serious ailments such as cancers and heart disease have been neglected. This suggests that HCM shares move into the oncology space ahead of the pandemic was fortuitous.

     

    HCM shares - going it alone

    Partnering with Eli Lily was a coup in China a couple of years back. However, it is clearly the case that followers of the Hutchison China Meditech share price would regard the pharma group going it alone with its own blockbuster as being an advance over this.

    Surufatinib is Chi-Med’s move on its own in China, and has been approved for the treatment of neuroendocrine tumours. This could be approved in China as soon as by the end of this year, while FDA approval in the US may not arrive long after.

     

    Hutchison China Meditech share price: blockbuster lung cancer treatment?

    While different cancers instil different levels of fear and mortality, it is the case that lung cancer has been the north face of the Eiger in oncology. Therefore, Savolitinib, a treatment in which Chi-Med is partnered with Astrazeneca, bears all the hallmarks of being a blockbuster in the making.

    Brokers Deutsche Bank believe that when combined with Astra’s early stage lung cancer treatment Tagrisso, Savolitinib could be worth more than $1bn to the HCM share price. This compares a $4.5bn market capitalisation currently.

     

    How to trade shares with ATFX

    Looking to trade Hutchison China Meditech shares and other major company shares? Open a live or demo account with ATFX to get up to speed. Start trading now to benefit from competitive spreads, high-quality trade execution, and no commission.

    1. Register for an account or log in to your existing account

    2. Open MT4 either on your desktop or mobile

    3. Search for Hutchison China Meditech shares in the market watch or symbols window

    4. Choose your position size

    5. Hit buy or sell, and then confirm the trade

     

    HCM share price Nasdaq: daily chart technical target as high as $44

    From a technical perspective it would appear that HCM shares have been in a rising trend channel since the beginning of 2020. This rising trend channel has taken in the March support for the stock just below $15, as well as the 50 day / 200 day moving average golden cross buy signal seen at the end of June.
    The possibility is that while there is no weekly close back below the current floor of the channel at $28, we could be treated to a 3 - 6 months technical target at the price channel top of $44.

     

    Daily chart analysis showing Hutchison China MediTech share price daily movements for 2020

     

    Risk management

    Looking to learn more about risk management and how it can benefit your trading? Check out our Risk and reward ratio article for more insight.

    Take the opportunity to develop your risk management strategy. Understand five key risk management techniques to help you look after your funds.

    Last Updated: 10/11/2020

    This market commentary and analysis has been prepared for ATFX by a third party for general information purposes only. Any view expressed does not constitute a personal recommendation or solicitation to buy or sell as it does not take into account your personal circumstances or objectives, and should therefore not be interpreted as financial, investment or other advice, or relied upon as such. You should therefore seek independent advice before making any investment decisions. This information has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. We aim to establish and maintain and operate effective organisational and administrative arrangements with a view to taking all reasonable steps to prevent conflicts of interest from constituting or giving rise to a material risk of damage to the interests of our clients. The market data is derived from independent sources believed to be reliable, however we make no representation or warranty of its accuracy or completeness, and accept no responsibility for any consequence of its use by recipients. Reproduction of this information, in whole or in part, is not permitted.


     

    Recent news

    market news
    The Fed’s decision to bring Q2 GDP on stage, the dovish stance may collide with strong economic growth

    This week the market will usher in heavy guidance, including the Federal Reserve resolutio...

    Bitcoin - BTCUSD Cryptocurrencies
    Bitcoin price bubble re-emerges, how high can BTCUSD reach in 2021?

    The mania in cryptocurrencies is back, and Bitcoin prices, BTCUSD, are just 1200 USD from ...

    Shares share price earnings stocks Walmart
    Walmart shares price pandemic challenge

    It can be said that for retailers of all shapes and sizes 2020 to date has been a challeng...

    Indices Shares share price earnings stocks Cineworld
    Cineworld share price could slump to 33 from 44.79 as cash reserves run out

    Cineworld share price had a stellar return of 331.23% from its October low to November hig...

    Shares share price earnings stocks Topps Tiles
    Topps Tiles share price hit by early 2020 profits warning

    It can be said that there are few stocks and sectors outside the pharma area who can prove...